Abemaciclib: Difference between revisions

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

Revision as of 15:58, 2 November 2023 view source Alexander Berchansky (talk \| contribs) 29,637 edits No edit summary ← Older edit		Latest revision as of 14:24, 21 January 2024 view source Michal Harel (talk \| contribs) 31,761 edits No edit summary
Line 1:		Line 1:
	<StructureSection load='' size='340' side='right' caption='~~Caption for this structure~~' scene='10/1002442/Cv/1'>		<StructureSection load='' size='340' side='right' caption='Abemaciclib' scene='10/1002442/Cv/1'>
	Abemaciclib, sold under the brand name Verzenio among others, is a medication for the treatment of advanced or metastatic breast cancers. It was developed by Eli Lilly and it acts as a CDK inhibitor selective for [[cyclin-dependent kinases]] CDK4 and CDK6.<ref name="a3">PMID:26264704</ref> See also [https://en.wikipedia.org/wiki/Abemaciclib Abemaciclib] and [[CDK4]].		Abemaciclib, sold under the brand name Verzenio among others, is a medication for the treatment of advanced or metastatic breast cancers. It was developed by Eli Lilly and it acts as a CDK inhibitor selective for [[cyclin-dependent kinases]] CDK4 and CDK6.<ref name="a3">PMID:26264704</ref> See also [https://en.wikipedia.org/wiki/Abemaciclib Abemaciclib] and [[CDK4]].